Strategic Financial Concepts LLC Invests $1.46 Million in Illumina, Inc. (NASDAQ:ILMN)

Strategic Financial Concepts LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, HoldingsChannel reports. The fund bought 10,958 shares of the life sciences company’s stock, valued at approximately $1,464,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new position in Illumina during the 4th quarter valued at about $32,000. TD Private Client Wealth LLC raised its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares in the last quarter. V Square Quantitative Management LLC lifted its stake in shares of Illumina by 50.6% in the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after acquiring an additional 132 shares during the period. Finally, Private Trust Co. NA boosted its holdings in shares of Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after acquiring an additional 212 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. UBS Group lifted their price target on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Piper Sandler lifted their target price on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Barclays downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price target for the company from $130.00 to $100.00 in a report on Monday, February 10th. JPMorgan Chase & Co. lifted their price objective on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and cut their target price for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $159.45.

Illumina Stock Down 1.5 %

Illumina stock opened at $100.24 on Tuesday. The firm’s 50 day moving average price is $132.74 and its two-hundred day moving average price is $134.91. The firm has a market cap of $15.90 billion, a PE ratio of -13.05 and a beta of 1.10. Illumina, Inc. has a twelve month low of $99.35 and a twelve month high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. On average, research analysts predict that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.